Modality
Nanobody
MOA
IL-23i
Target
CD3
Pathway
mTOR
MSMesoFTD
Development Pipeline
Preclinical
~Feb 2019
→ ~May 2020
Phase 1
Aug 2020
→ Aug 2026
Phase 1Current
NCT06545835
221 pts·Meso
2023-01→TBD·Not yet recruiting
NCT05397555
1,398 pts·FTD
2020-08→2026-08·Active
1,619 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-08-134mo awayInterim· FTD
Trial Timeline
Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3
P1
Active
P1
Not yet…
Catalysts
Interim
2026-08-13 · 4mo away
FTD
ActiveNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06545835 | Phase 1 | Meso | Not yet recr... | 221 | Mayo |
| NCT05397555 | Phase 1 | FTD | Active | 1398 | CR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| SNY-4496 | Sanofi | Phase 2/3 | CD3 | |
| NVO-9630 | Novo Nordisk | Phase 2 | CD3 | |
| GSK-6983 | GSK | Phase 2 | ALK | |
| Motarapivir | GSK | Preclinical | AuroraA | |
| Zenotapinarof | Vertex Pharma | Preclinical | CD38 | |
| Miriglumide | Alnylam | Phase 3 | CD3 | |
| Bemasotorasib | Exelixis | Phase 2 | CD38 | |
| Talatuximab | Samsung Biologics | Preclinical | CD3 | |
| MDG-4513 | Madrigal Pharma | Phase 1/2 | CD3 | |
| Tirasotorasib | Viking Therapeutics | Phase 1 | CFTR |